Insulet presented feasibility study results for its Omnipod fully closed-loop automated insulin delivery system for Type 2 diabetes, showing a 24% increase in time-in-range to 68% average daily proportion compared to standard injections
Abbott announced FreeStyle Libre platform trial results from over 300 U.K. participants, demonstrating a 0.6 percentage point drop in HbA1c after four months and an additional 2.5 hours per day in healthy glucose range
Dexcom highlighted registry data showing its G7 continuous glucose monitor lowered A1c by 0.7% over one year in Type 2 diabetes patients not taking insulin, with greater reductions in those with higher baseline A1c
All three companies presented data at the 19th International Conference on Advanced Technologies and Treatments for Diabetes (ATTD) in Barcelona, focusing on expanding technology adoption among the larger Type 2 diabetes market
Insulet plans to launch a pivotal clinical trial (EVOLVE) later in 2026, with goals of FDA application in 2027 and commercial launch in 2028
The data demonstrates that continuous glucose monitoring and automated insulin delivery systems can increase time in healthy blood sugar range, lower A1c levels, and support weight management in Type 2 diabetes patients